NCT07166120 Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
| NCT ID | NCT07166120 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 112 participants |
| Start Date | 2025-09-11 |
| Primary Completion | 2027-03-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.
Eligibility Criteria
Eligibility Criteria for Clinicians: * Clinician from participating oncology/hematology clinic * At least 18 years of age * Can speak and understand English Inclusion Criteria for Patients: * Patient at participating clinic * Age 18-89 years * Current smoking (average cigarettes per day ≥5) * Can speak and understand English * Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline Exclusion Criteria for Patients: * Active use of smoking cessation medication (within the past 30 days) * Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days) * Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy) * Patients who were deemed by the investigator to be ineligible for participation in the trial